XORTX Therapeutics (XORTX Therapeutics) Current Accrued Expense : $0.13 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Current Accrued Expense?

XORTX Therapeutics's Current Accrued Expense for the quarter that ended in Sep. 2023 was $0.13 Mil.

XORTX Therapeutics's quarterly Current Accrued Expense increased from Mar. 2023 ($0.12 Mil) to Jun. 2023 ($0.12 Mil) and increased from Jun. 2023 ($0.12 Mil) to Sep. 2023 ($0.13 Mil).

XORTX Therapeutics's annual Current Accrued Expense declined from Dec. 2020 ($0.51 Mil) to Dec. 2021 ($0.23 Mil) and declined from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.15 Mil).

XORTX Therapeutics Current Accrued Expense Historical Data

The historical data trend for XORTX Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Current Accrued Expense Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Current Accrued Expense

Get a 7-Day Free Trial

0.28

0.42

0.51

0.23

0.15

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Current Accrued Expense	Get a 7-Day Free Trial															0.39	0.15	0.12	0.12	0.13

XORTX Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

XORTX Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.